Evidence map›Paper›PMID 29089059›Full record

ReviewPediatric rheumatology online journal2017

Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature.

E L Binns, E Moraitis, S Maillard, S Tansley, N McHugh, T S Jacques, L R Wedderburn, C Pilkington, S A Yasin, K Nistala and 1 more

Registry-linked trialOpen access · goldAbstract readCase ReportsReview
In one paragraph

Review in Pediatric rheumatology online journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04295785 (Clinical, Paraclinical, Functional Characteristics and Evolution of Juvenile Autoimmune Necrotizing Myopathies in a National Retrospective Cohort), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04295785 unknown statusnot on this mapstarted 2020, after this paper: background citation

Clinical, Paraclinical, Functional Characteristics and Evolution of Juvenile Autoimmune Necrotizing Myopathies in a National Retrospective Cohort

TypeobservationalSponsorCentral Hospital, Nancy, FranceRan2020 to 2020Enrolled10ConditionsImmune-Mediated Necrotizing Myopathy
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Juvenile Dermatomyositis-Clinical Phenotypes.Current rheumatology reports · 2019
    Review
  16. Article
  17. Autoantibodies in myositis.Nature reviews. Rheumatology · 2018
    Review
  18. Immune-Mediated Necrotizing Myopathy.Current rheumatology reports · 2018
    Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

E L BinnsInfection, Immunity, Inflammation and Programme, Great Ormond Street, UCL Great Ormond Street, Institute of Child Health, London, UK. emma.binns@southerndhb.govt.nz.
E MoraitisInfection, Immunity, Inflammation and Programme, Great Ormond Street, UCL Great Ormond Street, Institute of Child Health, London, UK.
S MaillardRheumatology Unit, Great Ormond Street Hospital for Children, London, UK.
S TansleyDepartment of Pharmacy and Pharmacology, University of Bath, Bath, UK.
N McHughDepartment of Pharmacy and Pharmacology, University of Bath, Bath, UK.
T S JacquesDevelopmental Biology and Cancer Programme, UCL Institute of Child Health, London, UK.
L R WedderburnInfection, Immunity, Inflammation and Programme, Great Ormond Street, UCL Great Ormond Street, Institute of Child Health, London, UK.
C PilkingtonRheumatology Unit, Great Ormond Street Hospital for Children, London, UK.
S A YasinInfection, Immunity, Inflammation and Programme, Great Ormond Street, UCL Great Ormond Street, Institute of Child Health, London, UK.
K NistalaRheumatology Unit, Great Ormond Street Hospital for Children, London, UK.
UK Juvenile Dermatomyositis Research Group (UK and Ireland)
University College London · GBGreat Ormond Street Hospital · GBUniversity of Bath · GBGreat Ormond Street Hospital for Children NHS Foundation Trust · GBVersus Arthritis · GB

Funding

Wellcome Trust 085860Wellcome Trust 097259
6 · The paper itself

Abstract

backgroundAnti-Signal Recognition Particle associated myopathy is a clinically and histopathologically distinct subgroup of Juvenile Idiopathic Inflammatory Myositis, which is under-recognised in children and fails to respond to conventional first line therapies. We present three cases where remission was successfully induced using combination therapy with intensive rehabilitation. CASE PRESENTATIONS: Three new patients are reported. All 3 cases presented with profound, rapid-onset, proximal myopathy and markedly raised CK, but no rash. Histology revealed a destructive myopathy characterized by scattered atrophic and necrotic fibres with little or no inflammatory infiltrate. All 3 patients responded to induction with cyclophosphamide, IVIG and rituximab, in conjunction with intensive physiotherapy and methotrexate as the maintenance agent. Our patients regained near-normal strength (MMT > 70/80), in contrast with the current literature where >50% of cases reported severe residual weakness. A literature search on paediatric anti-SRP myositis was performed to June 2016; PubMed was screened using a combination of the following terms: signal recognition particle, autoantibodies, antibodies, myositis, muscular diseases, skeletal muscle, childhood, paediatric, juvenile. Articles in a foreign language were excluded. Nine case studies were found.

conclusionThis paper supports the hypothesis that anti-SRP myositis is distinct from other JIIM. It is an important differential to JDM and should be considered where there is severe weakness without rash or if highly elevated muscle enzymes (CK > 10,000 U/l) are found. Early identification is essential to initiate aggressive medical and physical therapy. Greater international collaboration and long-term follow-up data is needed to establish the most effective treatment strategy for this rare group of patients.

Indexed as

AdolescentAutoantibodiesChildCyclophosphamideDiagnosis, DifferentialFemaleHumansImmunoglobulins, IntravenousMethotrexateMuscle, SkeletalMyositisRituximabSignal Recognition ParticleTreatment OutcomeAutoantibodiesCyclophosphamideImmunoglobulins, IntravenousMethotrexateRituximabSignal Recognition Particle

Identifiers

PMID29089059
PMCPMC5664807
OpenAlexW2766028155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.